Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Clinical trial NCT00261365 · COMPLETED

Trial details

NCT number: NCT00261365
Sponsor: Bristol-Myers Squibb
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Unresectable Stage III or IV Malignant Melanoma

Start date: 2005-11-01
Primary completion: 2007-10-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.